Navigation Links
Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Date:11/1/2007

nces in 2008.

Poniard is continuing to evaluate picoplatin administered once every two weeks in the FOLPI regimen in its ongoing Phase 1 trial and has not yet reached the maximum tolerated dose for this dosing regimen.

About Picoplatin

Picoplatin has an improved safety profile compared to existing platinum- based chemotherapeutics and was designed to overcome platinum resistance. Poniard's strategy is to develop picoplatin as a platform product that can be used second-line in patients who are resistant or refractory to currently available platinums, such as small cell lung cancer (SCLC) patients, and first-line in patients, such as CRC patients, who cannot tolerate the toxicity profile of currently marketed platinums. We also plan to advance the use of picoplatin in new combination regimens in which platinums are not currently used, such as in the treatment of hormone-refractory prostate cancer (HRPC) patients, in order to improve efficacy. In addition to the Phase 2 trial in metastatic CRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in SCLC. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint.

The Company is also evaluating intravenous picoplatin in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic HRPC. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

Picoplatin has been tested in more than 600 patients in Phase 1 and 2 safety and efficacy studies.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead pla
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... ST. LOUIS, July 29, 2014  Express Scripts Holding ... quarter net income attributable to Express Scripts stockholders of ... per diluted share, as detailed in Table 4, was ... "We are well positioned to serve our clients with ... and to improve the health outcomes of our members," stated ...
(Date:7/29/2014)... 29, 2014 Regado Biosciences, Inc. (Nasdaq: ... Phase 3 clinical development of Revolixys™ Kit (previously known ... today announced that it will hold a conference call ... at 8:30 a.m. EDT to discuss its second quarter ... participants and investors may access the conference call by ...
(Date:7/29/2014)... VIEW, Calif. , July 29, 2014  Alexza ... that it is participating in two healthcare conferences during ... Conference and the Morgan Stanley Global Healthcare 2014 Conference. ... Morgan Stanley Conference.  The details on each event are ... Conference, Monday, August 11, 2014 in Boston ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3
(Date:7/30/2014)... Francisco, CA (PRWEB) July 30, 2014 ... capture and physician communication, launched an Observation Result ... in the hospital. pMD’s cardiology customers are using ... optimize revenue for their test interpretations for electrocardiograms, ... interprets tests in the hospital, the cardiology system ...
(Date:7/30/2014)... Regents Health Resources, a consulting firm traditionally ... care industry veteran Daryl Demonbreun and former St. Thomas ... company’s ambitious plans to grow into a full-service health ... along at a steady pace for nearly 20 years, ... says Bob Maier, founder and chief executive officer of ...
(Date:7/29/2014)... July 30, 2014 VisitandCare.com ... have been added to the company’s exclusive network to ... out of joint efforts — as top fertility clinics ... to offer affordable, state-of-the-art, and successful IVF treatments. , ... with a comprehensive study by professionals at VisitandCare.com. The ...
(Date:7/29/2014)... a well-known wedding dress manufacturer and retailer, has unveiled its ... this, it has announced that all of them are provided ... its old and new clients may now access the big ... are pleased to release the new collection of satin bridal ... amazing items. It is true that our satin bridal gowns ...
(Date:7/29/2014)... Phytceramides are a natural anti-aging tool for improving skin, ... , Today is the last day to nab a free download ... The book is also sold in hard copy. , "I am ... Phytoceramides were so new and very unknown in the U.S. ... says Kathy Heshelow, founder of Sublime Beauty®. "It is an easy ...
Breaking Medicine News(10 mins):Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3
... , MINNEAPOLIS, Aug. 31 The August edition ... Lotion can play in managing dry skin associated with the genetic skin ... that 40% of women have symptoms, like little red bumps on their ... , To help individuals find out more about dry ...
... , Safety tips also offered as fires threaten ... American Red Cross is on the scene offering evacuees a safe place ... scorch thousands of acres. Overnight, nearly 200 people took refuge from the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , , "If ...
... find tumors during minimally invasive surgery, researchers say , ... arm that can gently "feel" for cancerous tumors during ... , The device, invented at the University of Western ... will help surgeons better isolate tumors from softer surrounding ...
... , , Union members to ... , , LOS ANGELES and OAKLAND, Calif., Aug. ... California will picket outside their work sites for the next five weeks ... pickets will take place from 11:30 a.m. to 1:30 p.m. on Tuesday, ...
... , , , COCONUT ... ) the leading single source telehealth solution provider and ... savings accounts for unions, employers, and brokers, announced today that ... corporations and unions, will not only revolutionize the delivery of ...
... NEW YORK, Aug. 31 You may guess by reading ... a rare breed. He,s also a rare blood type: O-positive, "Code ... , , Make that a VERY dedicated blood donor: ... donation, the most on record for New York Blood Center (NYBC) and ...
Cached Medicine News:Health News:Family Circle Magazine Features AmLactin(R) in Article on Managing Dry Skin Associated With Keratosis Pilaris 2Health News:Red Cross Shelters Wildfire Evacuees 2Health News:Red Cross Shelters Wildfire Evacuees 3Health News:New Robotic Arm Has Softer Surgical Touch 2Health News:Kaiser Workers' Statewide Campaign Starts Tuesday 2Health News:e-Telmed, Inc., the Leading Telehealth Solution Provider, Signs Exclusive Agreement with Synergistic Healthcare 2Health News:This Guy's Got Blood, and Heart -- At 320 and Counting, Al Fischer Sets Record for Blood Donations 2Health News:This Guy's Got Blood, and Heart -- At 320 and Counting, Al Fischer Sets Record for Blood Donations 3Health News:This Guy's Got Blood, and Heart -- At 320 and Counting, Al Fischer Sets Record for Blood Donations 4
... Prep Swabsticks are saturated with a 10% ... available iodine. Povidone Iodine is virtually non-irritating ... is also non-staining to the skin or ... microbes on contact; they are sturdy tools ...
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
... Swabsticks are packaged in easy open, single-use ... saturated with precisely the correct amount of ... the safest possible product for the patient. ... an excellent combination of ethyl alcohol and ...
Medicine Products: